MENARINI SILICON BIOSYSTEMS SPA

Their core work

Menarini Silicon Biosystems is an Italian medtech company specializing in microfluidics and microfabricated medical devices — the kind of precision hardware that sits at the intersection of semiconductor manufacturing and life sciences. Their work spans both the fabrication side (advanced pilot line technologies for miniaturized systems) and the application side (medical devices built on microfabrication). As part of the Menarini pharmaceutical group with a dedicated biosystems division, they bring industrial-scale manufacturing credibility to research consortia working on microsystems for diagnostics and therapy. Their H2020 participation places them in high-complexity ECSEL and Innovation Action programs alongside semiconductor foundries, research institutes, and medical device companies.

What they specialise in

How they've shifted over time

In their first H2020 project (ADMONT, 2015–2019), Menarini Silicon Biosystems worked on foundational semiconductor manufacturing capabilities — advanced pilot lines for More-than-Moore technologies, with no topical keywords suggesting a broad, infrastructure-level contribution. By their second project (Moore4Medical, 2020–2023), the focus had sharpened clearly toward medical applications of microfabrication, with the keyword "open and enabling technology platforms" indicating a strategic interest in creating shared R&D infrastructure for the medtech sector. The trajectory moves from general microsystems manufacturing toward specifically medical device innovation, which aligns with the company's commercial identity as a biosystems specialist within a pharmaceutical group.

They are moving from broad semiconductor manufacturing participation toward becoming a specialist node in European medtech innovation ecosystems — likely future projects will combine microfabrication, diagnostics, and open platform development.

How they like to work

Menarini Silicon Biosystems has participated exclusively as a consortium partner, never leading a project — a consistent specialist-contributor pattern across both projects. Despite only two projects, they accumulated 75 unique partners across 13 countries, which points to participation in large, well-connected consortia (ECSEL programs routinely involve 30–50 partners). This suggests they are valued as an industrial implementation partner rather than a research driver — someone a coordinator calls on for fabrication credibility and industrial process know-how.

With 75 unique partners across 13 countries from just two projects, their network is disproportionately broad for their project count — a direct consequence of ECSEL Joint Undertaking programs that assemble pan-European semiconductor and medtech consortia. Their geographic reach is solidly European, spanning Western and Central Europe's semiconductor and medtech manufacturing corridors.

What sets them apart

Menarini Silicon Biosystems sits in a rare niche: an Italian private company combining pharmaceutical group backing (Menarini) with deep microsystems engineering capability (Silicon Biosystems), giving them both life-science application knowledge and semiconductor fabrication credibility in the same organization. Most medtech partners in EU consortia come from either the device engineering side or the biology side — this company credibly spans both. For consortium builders working on medical diagnostics, liquid biopsy, or microfabricated lab-on-chip devices, they offer an industrial partner with both technical depth and commercial route-to-market relevance.

Highlights from their portfolio

• ADMONT
  Their largest H2020 award (€784,631) and earliest project — an ECSEL Innovation Action on distributed pilot lines for More-than-Moore technologies, placing them inside Europe's core semiconductor manufacturing R&D infrastructure.
• Moore4Medical
  Marks a clear strategic pivot toward medical devices specifically, and introduces 'open and enabling technology platforms' as a keyword — signaling ambitions beyond single-product development toward shared medtech infrastructure.